Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Applied Therapeutics Inc's Business Segments
Applied Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Applied Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- License100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 1 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Applied Therapeutics Inc
Applied Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat diseases caused by dysfunction in specific molecular pathways. The company operates with the mission of addressing unmet medical needs and improving the lives of patients suffering from various debilitating conditions.
Applied Therapeutics is known for its innovative approach to drug development, leveraging insights from molecular biology, genetics, and clinical research to identify novel targets and develop therapies that have the potential to make a significant impact on patient outcomes. The company's pipeline consists of a diverse range of candidates targeting different disease areas, including rare genetic disorders, neurodegenerative diseases, and cardiovascular conditions.
One area of particular focus for Applied Therapeutics is rare monogenic diseases, where there is a clear genetic cause and a limited number of treatment options available. The company utilizes a precision medicine approach to identify specific gene mutations that are responsible for these conditions and develops therapies that target the underlying molecular pathways affected by these mutations. By addressing the root cause of the disease, Applied Therapeutics aims to provide effective and long-lasting treatments for patients.
Another area of interest for the company is neurodegenerative diseases such as Alzheimer's and Parkinson's. Applied Therapeutics recognizes the urgent need for effective therapies in these conditions, which have a significant impact on the quality of life for patients and their families. The company is actively researching and developing novel drugs that target specific molecular pathways involved in the progression of these diseases, with the aim of slowing down or halting their progression.
Cardiovascular diseases also represent a significant area of focus for Applied Therapeutics. These conditions, including heart failure and atherosclerosis, are major causes of morbidity and mortality worldwide. The company is dedicated to developing therapies that target specific molecular pathways involved in the development and progression of these diseases, with a focus on reducing inflammation and improving cardiac function.
Applied Therapeutics utilizes a multidisciplinary approach to drug discovery and development, with expertise in medicinal chemistry, genetics, pharmacology, and clinical research. The company collaborates with leading academic institutions, research organizations, and clinical experts to ensure the scientific rigor and clinical relevance of its programs. Furthermore, Applied Therapeutics actively seeks partnerships and collaborations with other pharmaceutical companies and investors to accelerate the development and commercialization of its therapies.
In summary, Applied Therapeutics Inc is a biopharmaceutical company that is committed to developing and commercializing innovative therapeutics for diseases caused by dysfunction in specific molecular pathways. Through its precision medicine approach, the company aims to provide effective and long-lasting treatments for patients suffering from rare genetic disorders, neurodegenerative diseases, and cardiovascular conditions. With a diverse pipeline and a collaborative approach to drug development, Applied Therapeutics is at the forefront of advancing the field of precision medicine and improving patient outcomes.
Applied Therapeutics is known for its innovative approach to drug development, leveraging insights from molecular biology, genetics, and clinical research to identify novel targets and develop therapies that have the potential to make a significant impact on patient outcomes. The company's pipeline consists of a diverse range of candidates targeting different disease areas, including rare genetic disorders, neurodegenerative diseases, and cardiovascular conditions.
One area of particular focus for Applied Therapeutics is rare monogenic diseases, where there is a clear genetic cause and a limited number of treatment options available. The company utilizes a precision medicine approach to identify specific gene mutations that are responsible for these conditions and develops therapies that target the underlying molecular pathways affected by these mutations. By addressing the root cause of the disease, Applied Therapeutics aims to provide effective and long-lasting treatments for patients.
Another area of interest for the company is neurodegenerative diseases such as Alzheimer's and Parkinson's. Applied Therapeutics recognizes the urgent need for effective therapies in these conditions, which have a significant impact on the quality of life for patients and their families. The company is actively researching and developing novel drugs that target specific molecular pathways involved in the progression of these diseases, with the aim of slowing down or halting their progression.
Cardiovascular diseases also represent a significant area of focus for Applied Therapeutics. These conditions, including heart failure and atherosclerosis, are major causes of morbidity and mortality worldwide. The company is dedicated to developing therapies that target specific molecular pathways involved in the development and progression of these diseases, with a focus on reducing inflammation and improving cardiac function.
Applied Therapeutics utilizes a multidisciplinary approach to drug discovery and development, with expertise in medicinal chemistry, genetics, pharmacology, and clinical research. The company collaborates with leading academic institutions, research organizations, and clinical experts to ensure the scientific rigor and clinical relevance of its programs. Furthermore, Applied Therapeutics actively seeks partnerships and collaborations with other pharmaceutical companies and investors to accelerate the development and commercialization of its therapies.
In summary, Applied Therapeutics Inc is a biopharmaceutical company that is committed to developing and commercializing innovative therapeutics for diseases caused by dysfunction in specific molecular pathways. Through its precision medicine approach, the company aims to provide effective and long-lasting treatments for patients suffering from rare genetic disorders, neurodegenerative diseases, and cardiovascular conditions. With a diverse pipeline and a collaborative approach to drug development, Applied Therapeutics is at the forefront of advancing the field of precision medicine and improving patient outcomes.
Applied Therapeutics Inc. is a biopharmaceutical company focused on the development of novel treatments for unmet medical needs, particularly in the field of metabolic and neurodegenerative diseases. The company has a strong emphasis on innovative therapies that leverage a deep understanding of disease mechanisms to provide targeted interventions.
Segments
1. Metabolic Diseases:
Applied Therapeutics is particularly focused on developing treatments for rare metabolic disorders. This segment is critical as it addresses the needs of patients suffering from diseases that are often overlooked by larger pharmaceutical companies due to their limited market size.
2. Neurodegenerative Disorders:
In this segment, the company aims to develop therapies that address conditions characterized by progressive degeneration of the structure and function of the nervous system. This includes focusing on diseases where currently available treatments are inadequate or non-existent.
3. Rare Diseases:
Many of the conditions the company targets fall under the category of rare diseases. The identification and development of therapeutic solutions for these conditions are pivotal, as they often affect small patient populations but can be life-altering and severely debilitating.
Products
1. AT-001:
This is Applied Therapeutics lead product candidate, designed for the treatment of galactosemia, a rare genetic disorder that affects the bodys ability to metabolize galactose. AT-001 aims to provide a novel approach to managing the disease by targeting the underlying biochemical pathways rather than just managing symptoms.
2. AT-007:
AT-007 is another significant candidate in the companys pipeline, targeting the treatment of diabetic complications and potentially neurodegenerative diseases. The mechanism of action involves modulation of key metabolic pathways, showing promise in preclinical and clinical studies.
3. Other Pipeline Candidates:
Applied Therapeutics has a variety of other candidates in its research and development pipeline, addressing various other metabolic and neurodegenerative conditions. These candidates are at different stages of testing, reflecting the companys commitment to expanding treatment options in areas with high unmet medical need.
Services
1. Clinical Trials:
The company invests heavily in conducting clinical trials to rigorously test the efficacy and safety of its drug candidates. This involves a comprehensive approach, from designing studies to enrolling patients and collecting data.
2. Regulatory Affairs:
Applied Therapeutics has a team dedicated to navigating the complex landscape of regulatory requirements necessary for bringing new drugs to market. This includes interactions with health authorities and submission of required documentation to ensure compliance.
3. Patient Advocacy and Involvement:
Understanding the rare and often life-altering nature of the diseases targeted, Applied Therapeutics emphasizes the importance of patient advocacy and involvement in the drug development process. Engagement with patient groups helps the company tailor its development programs to meet real-world patient needs.
4. Collaboration and Partnerships:
The company actively seeks collaborations with academic institutions, research organizations, and other pharmaceutical companies. These partnerships facilitate shared knowledge, resources, and expertise, enhancing the development pipeline and increasing the potential for successful outcomes.
5. Educational Initiatives:
Applied Therapeutics is involved in education initiatives aimed at increasing awareness about the metabolic and neurodegenerative diseases it targets. This may include providing information for healthcare professionals and advocating for better utilization of therapies.
In summary, Applied Therapeutics Inc. focuses on innovative biopharmaceutical solutions for various metabolic and neurodegenerative diseases, with a robust pipeline of products and a commitment to patient engagement and collaboration in the healthcare ecosystem. Its emphasis on addressing rare diseases underscores the companys mission to make substantial changes in the lives of patients with unmet medical needs.
Segments
1. Metabolic Diseases:
Applied Therapeutics is particularly focused on developing treatments for rare metabolic disorders. This segment is critical as it addresses the needs of patients suffering from diseases that are often overlooked by larger pharmaceutical companies due to their limited market size.
2. Neurodegenerative Disorders:
In this segment, the company aims to develop therapies that address conditions characterized by progressive degeneration of the structure and function of the nervous system. This includes focusing on diseases where currently available treatments are inadequate or non-existent.
3. Rare Diseases:
Many of the conditions the company targets fall under the category of rare diseases. The identification and development of therapeutic solutions for these conditions are pivotal, as they often affect small patient populations but can be life-altering and severely debilitating.
Products
1. AT-001:
This is Applied Therapeutics lead product candidate, designed for the treatment of galactosemia, a rare genetic disorder that affects the bodys ability to metabolize galactose. AT-001 aims to provide a novel approach to managing the disease by targeting the underlying biochemical pathways rather than just managing symptoms.
2. AT-007:
AT-007 is another significant candidate in the companys pipeline, targeting the treatment of diabetic complications and potentially neurodegenerative diseases. The mechanism of action involves modulation of key metabolic pathways, showing promise in preclinical and clinical studies.
3. Other Pipeline Candidates:
Applied Therapeutics has a variety of other candidates in its research and development pipeline, addressing various other metabolic and neurodegenerative conditions. These candidates are at different stages of testing, reflecting the companys commitment to expanding treatment options in areas with high unmet medical need.
Services
1. Clinical Trials:
The company invests heavily in conducting clinical trials to rigorously test the efficacy and safety of its drug candidates. This involves a comprehensive approach, from designing studies to enrolling patients and collecting data.
2. Regulatory Affairs:
Applied Therapeutics has a team dedicated to navigating the complex landscape of regulatory requirements necessary for bringing new drugs to market. This includes interactions with health authorities and submission of required documentation to ensure compliance.
3. Patient Advocacy and Involvement:
Understanding the rare and often life-altering nature of the diseases targeted, Applied Therapeutics emphasizes the importance of patient advocacy and involvement in the drug development process. Engagement with patient groups helps the company tailor its development programs to meet real-world patient needs.
4. Collaboration and Partnerships:
The company actively seeks collaborations with academic institutions, research organizations, and other pharmaceutical companies. These partnerships facilitate shared knowledge, resources, and expertise, enhancing the development pipeline and increasing the potential for successful outcomes.
5. Educational Initiatives:
Applied Therapeutics is involved in education initiatives aimed at increasing awareness about the metabolic and neurodegenerative diseases it targets. This may include providing information for healthcare professionals and advocating for better utilization of therapies.
In summary, Applied Therapeutics Inc. focuses on innovative biopharmaceutical solutions for various metabolic and neurodegenerative diseases, with a robust pipeline of products and a commitment to patient engagement and collaboration in the healthcare ecosystem. Its emphasis on addressing rare diseases underscores the companys mission to make substantial changes in the lives of patients with unmet medical needs.